Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, has announced that new results evaluating Proclarix in combination with imaging were published in BJU International.
The early detection of clinically significant prostate cancer decreases prostate cancer mortality. The use of multiparametric magnetic resonance imaging (mpMRI) has been a significant advance in prostate cancer diagnosis and is recommended in most current guidelines. Proclarix is a blood-based biomarker test aiding in the identification of prostate cancer.
The aim of the study highlighted here was the assessment of the diagnostic performance of Proclarix in combination with mpMRI. Blood samples from 721 men undergoing mpMRI followed by biopsy at University College London (UCL), London, and Vall d’Hebron University Hospital, Barcelona were analysed.
The combined Proclarix-MRI score's specificity (68%) was significantly (p<0.001) better compared to Proclarix (27%) or mpMRI (28%) alone. In addition, Proclarix by itself was found to be useful in men with indetermined imaging results (the MRI PI-RADS 3 subgroup) by outperforming PSA density in terms of specificity (25% vs 13%, p=0.004) at 100% sensitivity.
“Proclarix in combination with mpMRI reliably predicted clinically significant prostate cancer and ruled out men with no or indolent cancer. A large reduction of two thirds of unneeded biopsies was achieved” Prof. Mark Emberton from UCL commented and further added: “Combining imaging with biomarkers such as Proclarix is clearly the future in terms of prostate cancer risk stratification.”
BJUI is one of the most highly respected medical journals in the world, with a truly international range of published papers and appeal. For more than ninety years, it has provided invaluable practical information in the form of original articles, reviews, comments, surgical education articles, and translational science articles across the field of urology.
Proclarix is CE-certified under IVDR and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient’s risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer.
- Morote J, Pye H, Campistol M, et al. Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging [published online ahead of print, 2023 Mar 1]. BJU Int. 2023; doi:10.1111/bju.15998.
